SG10201602326RA - Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder - Google Patents
Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorderInfo
- Publication number
- SG10201602326RA SG10201602326RA SG10201602326RA SG10201602326RA SG10201602326RA SG 10201602326R A SG10201602326R A SG 10201602326RA SG 10201602326R A SG10201602326R A SG 10201602326RA SG 10201602326R A SG10201602326R A SG 10201602326RA SG 10201602326R A SG10201602326R A SG 10201602326RA
- Authority
- SG
- Singapore
- Prior art keywords
- brexpiprazole
- drug
- salt
- combinations
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471911P | 2011-04-05 | 2011-04-05 | |
| US201161580540P | 2011-12-27 | 2011-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201602326RA true SG10201602326RA (en) | 2016-04-28 |
Family
ID=46045045
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013069273A SG193468A1 (en) | 2011-04-05 | 2012-04-04 | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
| SG10201602326RA SG10201602326RA (en) | 2011-04-05 | 2012-04-04 | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013069273A SG193468A1 (en) | 2011-04-05 | 2012-04-04 | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US20140120185A1 (en) |
| EP (4) | EP3626243A1 (en) |
| JP (2) | JP5992924B2 (en) |
| KR (1) | KR101890450B1 (en) |
| CN (2) | CN103547260B (en) |
| AR (1) | AR085840A1 (en) |
| AU (1) | AU2012240864B2 (en) |
| CA (1) | CA2832157C (en) |
| CO (1) | CO6801769A2 (en) |
| CY (1) | CY1120567T1 (en) |
| DK (1) | DK2694043T3 (en) |
| EA (1) | EA035837B1 (en) |
| ES (1) | ES2654851T3 (en) |
| HK (1) | HK1246159A1 (en) |
| HR (1) | HRP20180098T1 (en) |
| HU (1) | HUE035542T2 (en) |
| IL (1) | IL228669B (en) |
| JO (2) | JOP20120083B1 (en) |
| LT (1) | LT2694043T (en) |
| MX (2) | MX370670B (en) |
| MY (1) | MY166936A (en) |
| NZ (1) | NZ615591A (en) |
| PL (1) | PL2694043T3 (en) |
| PT (1) | PT2694043T (en) |
| RS (1) | RS56802B1 (en) |
| SG (2) | SG193468A1 (en) |
| SI (1) | SI2694043T1 (en) |
| TW (1) | TWI636784B (en) |
| WO (1) | WO2012137971A1 (en) |
| ZA (1) | ZA201306981B (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3753B1 (en) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | Tablet comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
| JO3190B1 (en) * | 2011-10-19 | 2018-03-08 | Otsuka Pharma Co Ltd | Solution for oral administration |
| TW201332572A (en) * | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | Pharmaceutical preparation comprising substituted β -cyclodextrin |
| JOP20200109A1 (en) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | Injectable preparation |
| JOP20210047A1 (en) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | Prophylactic and/or therapeutic agent for behavioral and psychological symptoms associated with neurodegenerative disease or impulsive symptoms associated with mental disease containing brexpiprazole or salt thereof |
| CN106456634A (en) | 2014-04-22 | 2017-02-22 | 大塚制药株式会社 | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| WO2015188092A1 (en) * | 2014-06-06 | 2015-12-10 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
| CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| IL262065B2 (en) | 2016-04-01 | 2023-12-01 | Univ Pittsburgh Commonwealth Sys Higher Education | Regulatory device and associated method |
| WO2018033483A1 (en) | 2016-08-16 | 2018-02-22 | H E X A L Aktiengesellschaft | Pharmaceutical compositions of a benzothiophene compound |
| EP3500247B1 (en) | 2016-08-16 | 2020-05-27 | H e x a l Aktiengesellschaft | Immediate release tablet of a benzothiophene compound |
| EP3532064B1 (en) * | 2016-10-28 | 2020-07-29 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3501506B1 (en) * | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
| JP2019183095A (en) * | 2018-08-16 | 2019-10-24 | 株式会社Ｄｎｐファインケミカル | Adhesive powder, manufacturing method of adhesive tablet, adhesive tablet, and manufacturing method of member or component using the adhesive powder and tablet |
| JP6831354B2 (en) * | 2018-08-16 | 2021-02-17 | 株式会社Ｄｎｐファインケミカル | A tablet made of an adhesive composition, a method for producing the same, and a method for producing a member or part using the tablet. |
| AU2019366947A1 (en) * | 2018-10-24 | 2021-06-03 | Effector Therapeutics, Inc. | Crystalline forms of Mnk inhibitors |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| CA3138094A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| JPWO2021029020A1 (en) * | 2019-08-13 | 2021-02-18 | ||
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| CN113322299A (en) * | 2021-05-28 | 2021-08-31 | 南昌大学 | Drug target recognition method for depression and drug addiction diseases |
| US20240009181A1 (en) * | 2022-07-08 | 2024-01-11 | Jason Eric Schiffman | Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| IL123716A (en) * | 1997-03-27 | 2001-03-19 | Akzo Nobel Nv | Therapeutic combinations of mirtazapine and an antipsychotic agent |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| WO2003013492A1 (en) * | 2001-08-08 | 2003-02-20 | Eli Lilly And Company | Combination therapy for the treatment of neurological disorders |
| ATE376419T1 (en) * | 2002-12-27 | 2007-11-15 | Otsuka Pharma Co Ltd | CARBOSTYRIL DERIVATIVES WITH SELECTIVE SEROTONIN UPtake INHIBITORS, FOR THE TREATMENT OF MOOD DISEASES |
| EP1768653A4 (en) * | 2004-06-25 | 2012-08-01 | Univ Texas | Methods and compositions for the treatment of attention deficit hyperactivity disorder and hyperphenylalanemia |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (en) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | Heterocyclic compounds |
| JP4540700B2 (en) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | Medicine |
| BRPI0718318A2 (en) * | 2006-10-27 | 2013-11-26 | Janssen Pharmaceutica Nv | PROCESSES FOR TREATMENT OF BEHAVIOR DISORDER DISORDERS. |
| JP2008189616A (en) * | 2007-02-07 | 2008-08-21 | Mitsubishi Tanabe Pharma Corp | Therapeutic agent for attention-deficit hyperactivity disorder |
| JP2011136906A (en) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | Heterocyclic compound |
-
2012
- 2012-04-03 JO JOP/2012/0083A patent/JOP20120083B1/en active
- 2012-04-03 AR ARP120101135A patent/AR085840A1/en unknown
- 2012-04-03 TW TW101111875A patent/TWI636784B/en active
- 2012-04-04 ES ES12719460.3T patent/ES2654851T3/en active Active
- 2012-04-04 WO PCT/JP2012/059825 patent/WO2012137971A1/en active Application Filing
- 2012-04-04 MY MYPI2013701740A patent/MY166936A/en unknown
- 2012-04-04 CN CN201280017329.8A patent/CN103547260B/en active Active
- 2012-04-04 PT PT127194603T patent/PT2694043T/en unknown
- 2012-04-04 HU HUE12719460A patent/HUE035542T2/en unknown
- 2012-04-04 SG SG2013069273A patent/SG193468A1/en unknown
- 2012-04-04 EP EP19205895.6A patent/EP3626243A1/en not_active Withdrawn
- 2012-04-04 SG SG10201602326RA patent/SG10201602326RA/en unknown
- 2012-04-04 EA EA201391450A patent/EA035837B1/en not_active IP Right Cessation
- 2012-04-04 KR KR1020137029250A patent/KR101890450B1/en active IP Right Grant
- 2012-04-04 EP EP17198877.7A patent/EP3299018A1/en not_active Withdrawn
- 2012-04-04 SI SI201231192T patent/SI2694043T1/en unknown
- 2012-04-04 CA CA2832157A patent/CA2832157C/en active Active
- 2012-04-04 PL PL12719460T patent/PL2694043T3/en unknown
- 2012-04-04 CN CN201810096214.1A patent/CN108042808B/en active Active
- 2012-04-04 US US14/009,436 patent/US20140120185A1/en not_active Abandoned
- 2012-04-04 LT LTEP12719460.3T patent/LT2694043T/en unknown
- 2012-04-04 MX MX2013010796A patent/MX370670B/en active IP Right Grant
- 2012-04-04 EP EP12719460.3A patent/EP2694043B1/en not_active Revoked
- 2012-04-04 DK DK12719460.3T patent/DK2694043T3/en active
- 2012-04-04 JP JP2013546481A patent/JP5992924B2/en active Active
- 2012-04-04 RS RS20180064A patent/RS56802B1/en unknown
- 2012-04-04 EP EP22155365.4A patent/EP4023223A1/en active Pending
- 2012-04-04 NZ NZ615591A patent/NZ615591A/en unknown
- 2012-04-04 AU AU2012240864A patent/AU2012240864B2/en active Active
-
2013
- 2013-09-17 ZA ZA2013/06981A patent/ZA201306981B/en unknown
- 2013-09-20 MX MX2019015237A patent/MX2019015237A/en unknown
- 2013-10-01 IL IL228669A patent/IL228669B/en active IP Right Grant
- 2013-11-05 CO CO13261085A patent/CO6801769A2/en not_active Application Discontinuation
-
2014
- 2014-05-09 HK HK18105601.0A patent/HK1246159A1/en unknown
-
2016
- 2016-08-18 JP JP2016160872A patent/JP2017031155A/en active Pending
- 2016-12-21 US US15/386,289 patent/US20170100395A1/en not_active Abandoned
-
2017
- 2017-10-19 US US15/788,102 patent/US20180042923A1/en not_active Abandoned
-
2018
- 2018-01-17 CY CY20181100057T patent/CY1120567T1/en unknown
- 2018-01-18 HR HRP20180098TT patent/HRP20180098T1/en unknown
- 2018-07-20 US US16/041,246 patent/US20180325894A1/en not_active Abandoned
-
2021
- 2021-02-25 JO JOP/2021/0035A patent/JOP20210035A1/en unknown
- 2021-03-10 US US17/197,725 patent/US20220000861A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL228669B (en) | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder | |
| IL228925A0 (en) | Benzothiazole compounds and their pharmaceutical use | |
| IL239278B (en) | A compound including pyridine or pyrimidine and a non-aryl-heterocyclic amine, a medicament and the compound for use in the prophylaxis or treatment of epilepsy or neurodegenerative disease | |
| EP2751270A4 (en) | Oligomer-conjugate complexes and their use | |
| GB201115711D0 (en) | Phyto-cannabinoids for use in the treatment of cancer | |
| IL229474A0 (en) | Cannabinoids for use in the treatment of neuropatich pain | |
| GB201120993D0 (en) | Novel compounds and their use in therapy | |
| HK1201454A1 (en) | Therapeutic agents and uses thereof | |
| TWI559929B (en) | Pharmaceutical composition for use in the treatment of a neurodegenerative disease | |
| IL230997A (en) | Pyrimidine pde10 inhibitors and their use in the preparation of medicaments for treating a neurological or psychiatric disorder | |
| ZA201502290B (en) | 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and ist associated disorders | |
| EP2718283A4 (en) | Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof | |
| HK1248704A1 (en) | Aminoindane compounds and use thereof in treating pain | |
| EP2817304A4 (en) | Novel compounds and their use in therapy | |
| HK1212255A1 (en) | Artemisinin and its derivatives for use in the treatment of kidney disease | |
| HK1196535A1 (en) | Salt and medical use | |
| HK1258668A1 (en) | Compounds for use in the treatment of intermittent explosive disorder | |
| ZA201501503B (en) | Bio-inoculant and use thereof for treatment of effluents | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| GB201218084D0 (en) | Novel compounds and methods for use in medicine | |
| SG11201402395YA (en) | Continuous body ofwristbands and wristband | |
| EP2744786A4 (en) | Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer | |
| HRP20181746T1 (en) | Trpc4 modulators for use in the treatment or prevention of pain | |
| HK1199729A1 (en) | Aldh-2 inhibitors in the treatment of addiction aldh-2 |